DUBLIN--(BUSINESS WIRE)--The "Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering.
The HNC Asia-Pacific market will be valued at $424.5m in 2023, growing from $265.9m in 2016 at a CAGR of 6.9%.
The HNC market is characterized by a small selection of marketed drug options, consisting of chemotherapies, targeted therapies (anti-EGFR), and immunotherapies (PD1/PD-L1 inhibitor). Historically, cytotoxic chemotherapies have made up the bulk of the HNC market. Little competition currently exists in the HNC market, leaving an area of considerable opportunity for interested newcomers. Currently, four targeted therapies are available in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo and Keytruda. The remainder of this market is composed of generics. Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less reliant on chemotherapy options.
With the approval of Keytruda in Australia, and Opdivo in Australia, South Korea and Japan, there has been an increase in targeted therapy options. Additionally avelumab (a PD-L1 inhibitor) is likely to be approved in APAC countries at the end of the forecast period, as it is currently undergoing Phase III trials in Japan, Australia and South Korea.
A number of mAbs are in development in HNC for the inhibition of various different pathways and signaling systems. Many companies are following a strategy of developing products with similar mechanisms of action to those of existing products already approved in either HNC or other oncology indications. EGFR and PD-1/PD-L1 are the most commonly addressed targets in the current pipeline.
However, there are also many innovative products in the HNC pipeline, which reflects a deepening scientific understanding of the underlying pathophysiology of HNC and the growing list of molecules that have been implicated in the initiation and progression of the disease.
- How will immune checkpoint inhibitors such as Opdivo, Keytruda and Imfinzi contribute to growth?
- What effect will patent expirations of branded therapies have on market value?
- The HNC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as the lack of targeted therapies available for locally advanced HNC patients?
- What implications will the increased focus on targeted therapies have on the future of HNC treatment?
- Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of Keytruda, Opdivo and Bavencio to treat locally advanced HNC patients affect the competitive landscape, with no immunotherapy currently available to address this patient subset?
- Licensing deals are the most common form of strategic alliance in HNC, with total deal values ranging from under $10m to over $1 billion.
Key Topics Covered:
1 Table of Contents
3 Marketed Products
4 Pipeline Analysis
5 Clinical Trial Analysis
6 Multi-scenario Forecast
7 Drivers and Barriers
8 Deals and Strategic Consolidations
- Biotech Pharmaceutical Co.
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Merck & Co.
For more information about this report visit https://www.researchandmarkets.com/research/hrs3b9/asiapacific_head?w=4